GRI Bio develops oral drug candidates for lung fibrosis and autoimmune diseases such as lupus. GRI reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 10 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 24 | Ascendiant Capital | Target lowered | Buy | |
| Jun 1 | Ascendiant Capital | Maintained | Buy |
Seasonality
How GRI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in GRI in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRI is in one of them and how their past GRI trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GRI in an article yet. Here's the latest on the wider market.
About GRI Bio
GRI Bio is a biopharmaceutical company based in La Jolla, California, that is developing oral medicines for diseases driven by an overactive immune system. Its lead candidate, GRI-0621, is being studied for idiopathic pulmonary fibrosis, a progressive disease that scars the lungs. A second candidate, GRI-0803, is in early development for lupus, an autoimmune disease. The company does not yet have any approved products, and its intended patients are people living with these serious conditions.
- Headquarters
- La Jolla, CA